Human albumin market analysis: China's overall market size is about 22.9 billion yuan

Published Date: 2023-01-19
Human serum albumin is a kind of blood product, commonly known as "life product" and "life-saving medicine". It is extracted and processed from the blood of healthy people and injected directly into the patient's body. Its main function is to enhance human immunity Strength and resistance. The market price is 300 to 400 yuan a bottle. Clinically, it is mainly used for the treatment of shock caused by blood loss trauma and burns, cerebral edema, liver cirrhosis, edema or ascites caused by kidney disease, and the treatment of low protein Blood patients.

China's blood product industry has strict collection standards and regulatory policies, making access difficult. Since 1985, China has banned the import of other varieties except for human albumin, which has a large gap between supply and demand. The blood product industry implements the GMP access system. The state no longer approves new blood product manufacturers, and the threat of new entrants in the industry is basically eliminated. The country allows the import of recombinant human coagulation factor VIII (but the import of coagulation factor VIII derived from human plasma is still not allowed).

The price of human serum albumin in my country is relatively low, and the international price is much higher than that in China, so the import of human serum albumin is very small. After that, the international market price continued to adjust and was lower than that in my country. However, due to the high circulation costs such as import taxes and dealer profits, only Bellin imports a very small amount of human albumin from China.

Albumin accounts for 52%-56% of the total plasma protein in healthy people, and its main function is to maintain the normal colloid osmotic pressure of plasma (accounting for 70%-80% of the total colloid osmotic pressure of plasma). The volume has been increasing year by year, with the batch release volume reaching 60.38 million bottles. As of the first quarter, the batch release volume of human serum albumin in my country was 11.62 million bottles.

From the perspective of the batch issuance structure of human serum albumin in China, the proportion of domestic human serum albumin in China is on a downward trend, and the proportion of domestic production has dropped from 42.57% to 35.12%; as of the first quarter of 2021, the batch issuance volume of domestic human serum albumin The proportion increased to 45.27%.

According to statistics, the overall market size of domestic human albumin is about 22.9 billion yuan. Hospital sales of human serum albumin samples were 4.22 billion yuan, a year-on-year increase of 11.3%, and the sales volume of human serum albumin samples in hospitals was 11.085 million bottles.

According to Hengzhou Primus, limited by the scale of plasma collection and separation and extraction technology, the domestic supply of human serum albumin is limited and cannot meet the increasing clinical needs. Judging from the batch release data over the years, imports have become the main supply source of domestic human serum albumin, and the proportion has increased year by year. During the epidemic, in order to alleviate the shortage of blood product supply caused by the reduction in plasma collection, relevant departments in China and the United States shortened the quarantine period. The China Food and Drug Administration shortened the quarantine period from 90 days to 60 days, while the US FDA shortened the 60-day quarantine period to 45 days. In my country's Chinese albumin industry, the first echelon is the international large-scale blood product companies such as Jet Behring, Octapharma, Gilifu and Baxter, with a large number of albumin batch releases. Followed by large domestic blood product companies, such as Shuanglin Bio, Boya Bio, Tiantan Bio, Hualan Bio, etc., followed closely by the number of batches issued.

Since then, due to various reasons such as the restructuring of plasma centers in my country, the sharp reduction in the amount of plasma input, and the increase in demand, the price of human serum albumin has skyrocketed, and the price advantage of human serum albumin in the international market can be reflected. At the same time, in order to To meet domestic demand, the country has lowered the tariffs on imported blood products, the impetus for imported products has increased significantly, and the proportion of imported human serum albumin has been on an upward trend.

The National Development and Reform Commission set a price for human serum albumin, and the price of 10 grams of 50ml human serum albumin injection did not rise but fell, from 330 yuan to 259 yuan. This move immediately led to a backlash from manufacturers, and some manufacturers expressed that they would take back the human albumin injections sold to hospitals and stop producing products. Under the strong feedback from the market, in the second half of the year, the price of local development and reform commissions loosened, and the highest price of human serum albumin gradually rose back to the original price of 330 yuan. Even so, there are prices and no goods on the market.